Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages

  Kim, Su Jung ^a   Kim, Dong Wan ^a   Kim, Tae Min ^a   Lee, Se Hoon ^a   Heo, Dae Seog ^a   Bang, Yung Jue ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; FLUORINE 18;

ADENOCARCINOMA; ADOLESCENT; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHOMA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; VISUAL DISORDER; WEIGHT GAIN;

ADENOCARCINOMA; ADOLESCENT; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 84863944214     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.9766     Document Type: Article

References (15)

1. Solomon B, Bang YJ, Camidge DR, et al: Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC). 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, November 16-19, 2010 (abstr 369)
2. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
3. Koh Y, Kim DW, Kim TM, et al: Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: Suggestion for an effective screening strategy for these tumors. J Thorac Oncol 6:905-912, 2011
4. Koivunen JP, Mermel C, Zejnullahu K, et al: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283, 2008
5. Weinstein IB, Joe AK: Mechanisms of disease: Oncogene addiction - A rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448-457, 2006 (Pubitemid 44203817)
6. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
7. Kutok JL, Aster JC: Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 20:3691-3702, 2002 (Pubitemid 34983230)
8. George RE, Sanda T, Hanna M, et al: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978, 2008
9. Pulford K, Lamant L, Espinos E, et al: The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 61:2939-2953, 2004 (Pubitemid 40104592)
10. Cessna MH, Zhou H, Sanger WG, et al: Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: A study of 135 cases. Mod Pathol 15:931-938, 2002
11. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739, 2010
12. Lovly CM, Heuckmann JM, de Stanchina E, et al: Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71:4920-4931, 2011
13. Sakamoto H, Tsukaguchi T, Hiroshima S, et al: CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679-690, 2011
14. Katayama R, Khan TM, Benes C, et al: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 108:7535-7540, 2011
15. Normant E, Paez G, West KA, et al: The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30:2581-2586, 2011